Simply Oncology

Dr Michael Rowe is a Clinical Oncologist based in Cornwall having completed speciality training in 2024. He has recently held the position of Chair of the National Oncology Trainees Collaborative for Healthcare Research (NOTCH) and has overseen and run a number of national multicentre studies including the first trainee-led national retrospective observational study on tolerance of anticancer therapy in the elderly (TOASTIE). He is on the study management group for current active NOTCH studies: HNSCCUP (head and neck cancer of unknown primary), ChILI (checkpoint induced liver injury) and DeACT (de-esclation of treatment in anal cancer in patients with comorbidities).
 He has co-authored a national bladder cancer radiotherapy dosing and fractionation guideline for the Royal College of Radiologists. He specialises in the treatment of urological, upper gastrointestinal and hepatobiliary cancers.